American Heart Journal
Volume 154, Issue 1 , Pages 54-61 , July 2007

Global outcomes of ST-elevation myocardial infarction: Comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial

  • Benjamin A. Steinberg, BA

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Nazanin Moghbeli, MD

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Jacqueline Buros, BA

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Mikhail Ruda, MD

      Affiliations

    • National Institute of Cardiology, Warsaw, Poland
    • ,
  • Alexander Parkhomenko, MD

      Affiliations

    • Institute of Cardiology, Kiev, Ukraine
    • ,
  • B. Soma Raju, MD

      Affiliations

    • Care Hospital, Hyderabad, India
    • ,
  • Armando García-Castillo, MD, FACC

      Affiliations

    • Hospital de'Enfermedades Cardiovasculares y del Torax, Monterrey, Mexico
    • ,
  • Marianna Janion, MD, PhD

      Affiliations

    • Swietokrzyskie Centrum Kardiologii, Kielce, Poland
    • ,
  • José C. Nicolau, MD, PhD, FACC

      Affiliations

    • Heart Institute, University of Sao Paulo Medical School, Sao Paulo, Brazil
    • ,
  • Keith A.A. Fox, MB, ChB

      Affiliations

    • University of Edinburgh, Cardiovascular Research, Edinburgh, United Kingdom
    • ,
  • David A. Morrow, MD, MPH, FACC

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • C. Michael Gibson, MS, MD, FACC

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Elliott M. Antman, MD, FACC

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, MA
    • Corresponding Author InformationReprint requests: Elliott M. Antman, MD, TIMI Study Group, 350 Longwood Avenue, Boston, MA 02115.

Received 30 November 2006 ,Accepted 28 March 2007.

References 

  1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20
  2. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet. 2006;367:579–588
  3. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477–1488
  4. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519–1530
  5. Bahit MC, Cannon CP, Antman EM, et al. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 trial and TIMI 9 registry. Am Heart J. 2003;145:109–117
  6. Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 2002;90:358–363
  7. Wiviott S, Morrow D, Giugliano R, et al. Performance of the thrombolysis in myocardial infarction risk index for early acute coronary syndrome in the National Registry of Myocardial Infarction: a simple risk index predicts mortality in both ST and non–ST elevation myocardial infarction. J Am Coll Cardiol. 2003;41(Suppl A):365A–366A
  8. Yan AT, Jong P, Yan RT, et al. Clinical trial-derived risk model may not generalize to real-world patients with acute coronary syndrome. Am Heart J. 2004;148:1020–1027
  9. Pilote L, Califf RM, Sapp S, et al. Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med. 1995;333:565–572
  10. Saleh SS, Hannan EL, Ting L. A multistate comparison of patient characteristics, outcomes, and treatment practices in acute myocardial infarction. Am J Cardiol. 2005;96:1190–1196
  11. Giugliano RP, Llevadot J, Wilcox RG, et al. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J. 2001;22:1702–1715
  12. Van de Werf F, Topol EJ, Lee KL, et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. JAMA. 1995;273:1586–1591
  13. Orlandini A, Diaz R, Wojdyla D, et al. Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur Heart J. 2006;27:527–533
  14. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet. 2001;358:1571–1575
  15. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J. 2005;149:217–226
  16. World Bank Development Indicators Database. In: World Bank; 2004.
  17. Norton EC. Computing interaction effects and standard errors in logit and probit models. Stata J. 2004;4:103–116
  18. Statacorp . In: Stata Statistical Software: Release 9.2. Statacorp (Tex): College Station; 2005;
  19. Gross CP, Krumholz HM, Wye GV, et al. Does random treatment assignment cause harm to research participants?. PLoS Med. 2006;3:e188
  20. Alter DA, Chong A, Austin PC, et al. Socioeconomic status and mortality after acute myocardial infarction. Ann Intern Med. 2006;144:82–93
  21. Banks J, Marmot M, Oldfield Z, et al. Disease and disadvantage in the United States and in England. JAMA. 2006;295:2037–2045

 Mr Steinberg is a research fellow supported by Sarnoff Cardiovascular Research Foundation, Great Falls, VA.

PII: S0002-8703(07)00275-X

doi: 10.1016/j.ahj.2007.03.047

American Heart Journal
Volume 154, Issue 1 , Pages 54-61 , July 2007

Article Tools

* Image Usage & Resolution